Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

NCT02102022 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT02102022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02102022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
Lead sponsor
Polaris Group
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2014
Completion date
February 29, 2020
Enrollment
140 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal (gi) malignancies, colorectal cancer, gastric cancer, hepatocellular carcinoma